This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): gefitinib, ZD1839
Description: Iressa was the first marketed epidermal growth factor receptor (EGFR) inhibitor.
Deal Structure: In July 2014, Qiagen announced a collaboration agreement with AstraZeneca for the co-development and commercialization of a liquid biopsy-based companion diagnostic to be paired with IRESSA.
Pink Sheet Chart: Iressa FDA Reviewers
Pink Sheet Chart: Iressa Clinical Development
Additional information available to subscribers only: